In this week’s Pharma Pulse, Lilly brings Zepbound and Foundayo to Hims & Hers, Swisslog Healthcare expands its Tenutō cold storage line, and FDA adds a NAION warning across the GLP-1 class.
|Podcasts|July 8, 2022
Addressing Rising Rx Costs
Author(s)Nicholas Saraceno, Senior Editor, Julian Upton
How did the industry get here and what alternatives can be sought out?
Advertisement
Nelly Rose, PharmD, VP of clinical consulting for NFP, an insurance broker and consultant that provides solutions to clients that span numerous industries, addresses the increase in prescription drug spending, along with ways to find more affordable options for driving down pharmacy spend, including the impact of biosimilars in the marketplace.
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Advertisement
Related to this article
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
CVS Health’s Breakup: A Turning Point for Pharma Supply Chains or a Redistribution of Market Power?
2
Pharma Pulse: Lilly and Hims & Hers Team Up, Swisslog Expands Tenutō Cold Storage
3
Why the Next Wave of Drug Launches Will Be Won on Market Access
4
When Drug Pricing Collides With Politics
5